For instance, it has previously been reported that targeting IL-6/JAK2/STAT3 signaling axis with FDA-approved agents, alone or combinatorially with HER2 inhibitors substantially repressed the tumorigenic properties of HR−/HER2+ breast cancer (BC)39. This evidence concerns the gene IL6 and breast carcinoma.